- Home
- FHN vs GALT Comparison
FHN vs GALT Comparison
Compare FHN & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- GALT
- Stock Information
- Founded
- FHN 1864
- GALT 2000
- Country
- FHN United States
- GALT United States
- Employees
- FHN N/A
- GALT N/A
- Industry
- FHN Major Banks
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- GALT Health Care
- Exchange
- FHN Nasdaq
- GALT Nasdaq
- Market Cap
- FHN 11.0B
- GALT 232.3M
- IPO Year
- FHN N/A
- GALT N/A
- Fundamental
- Price
- FHN $22.01
- GALT $4.63
- Analyst Decision
- FHN Buy
- GALT Strong Buy
- Analyst Count
- FHN 17
- GALT 3
- Target Price
- FHN $23.32
- GALT $6.00
- AVG Volume (30 Days)
- FHN 11.0M
- GALT 342.7K
- Earning Date
- FHN 10-15-2025
- GALT 11-12-2025
- Dividend Yield
- FHN 2.67%
- GALT N/A
- EPS Growth
- FHN 28.04
- GALT N/A
- EPS
- FHN 1.55
- GALT N/A
- Revenue
- FHN $3,083,000,000.00
- GALT N/A
- Revenue This Year
- FHN $10.95
- GALT N/A
- Revenue Next Year
- FHN $3.68
- GALT N/A
- P/E Ratio
- FHN $14.50
- GALT N/A
- Revenue Growth
- FHN 4.62
- GALT N/A
- 52 Week Low
- FHN $14.83
- GALT $0.73
- 52 Week High
- FHN $23.08
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- FHN 45.78
- GALT 54.43
- Support Level
- FHN $21.99
- GALT $4.21
- Resistance Level
- FHN $23.08
- GALT $6.55
- Average True Range (ATR)
- FHN 0.45
- GALT 0.46
- MACD
- FHN -0.07
- GALT -0.01
- Stochastic Oscillator
- FHN 5.91
- GALT 27.48
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.